Pharmaceuticals, Biotechnology and Life Sciences
A study that was presented at the American Diabetes Association’s Scientific sessions on Monday showed that treatment with autoantigen specific therapies, such as Alum-GAD, is safe to give to children with an increased risk for developing type 1 diabetes, however, it does not prevent the development of the disease.
Sanofi and Regeneron Pharmaceuticals have reported positive results from two Phase 3b/4 ODYSSEY-DM trials in patients with diabetes.
Eli Lilly plans to invest $850 million in its U.S. operations in 2017, the company said Friday.
Latino population in the United States of America have higher rates of cardio-metabolic diseases than in rest of the population, said David Kerr, director of Innovation and Research for the William Sansum Diabetes center.
AstraZeneca has reported results of the first large real-world evidence study of its kind evaluating the risk of hospitalisation for heart failure and death from any cause in patients with type-2 diabetes (T2D) receiving treatment with a newer class of diabetes medicines, SGLT-2 inhibitors (SGLT-2i).
The growing incidence of more Western lifestyle diseases such as cardiovascular disease (CVD), cancer, diabetes and respiratory disease, in addition to infectious and parasitic illness, will present the pharmaceutical industry in Africa with a business opportunity of $40.8 billion in 2019.
Eli Lilly has updated its Trulicity label to now include use in combination with basal insulin for adults with type 2 diabetes.
UPDATE contains comment from Lilly
Eli Lilly has quit from a research and licence agreement with a Paris-listed clinical stage pharmaceutical company Adocia, the French company said on Friday.
French drugmaker focused on diabetes treatments Poxel, said it expectedly did not generate meaningful revenues in the fourth quarter of 2016, but it is on track for developing two of its programs.
The European Commission has cleared Sanofi’s Suliqua in combination with metformin, type 2 diabetes treatment, for European adult patients.